Preeclampsia Screening Trial to Improve Outcomes (PRESTO)
Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy
The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.
The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.
Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.
Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Tae Stallworth
- Puhelinnumero: 770-742-8942 |
- Sähköposti: tae.stallworth@emory.edu
Opiskelupaikat
-
-
Georgia
-
Decatur, Georgia, Yhdysvallat, 30033
- Emory Decatur Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Pregnant persons aged 18 years or older.
- Singleton pregnancy.
- Gestational age from 23 weeks 0 days through 33 weeks 6 days.
- Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
- Provision of signed informed consent (English- or Spanish-speaking).
Exclusion Criteria:
- Enrollment in another therapeutic interventional trial with a primary outcome of HDP
- Receipt of intravenous heparin during hospitalization.
- Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
- Prior study enrollment during the current pregnancy.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Diagnostiikka
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Active Comparator: Blinded Test Results (Phase A)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care. Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
Muut nimet:
|
|
Kokeellinen: Real Time Results (Phase B)
Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study. During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test. |
Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.
Muut nimet:
sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Pregnancy latency
Aikaikkuna: At delivery (up to 40 weeks of gestation)
|
Time from admission to delivery |
At delivery (up to 40 weeks of gestation)
|
|
Participants with maternal adverse outcomes
Aikaikkuna: From enrollment until post-natal discharge (on average 10 days post-delivery)
|
The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive. |
From enrollment until post-natal discharge (on average 10 days post-delivery)
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of participants who require hospital admission
Aikaikkuna: From enrollment up to 37 weeks of gestation
|
Number of participants who require hospital admission during study participation, collected form medical records. |
From enrollment up to 37 weeks of gestation
|
|
Number of participants with indicated delivery within 14 days of presentation
Aikaikkuna: Up to 14 days from enrollment
|
Participants who require delivery within 14 days of presentation |
Up to 14 days from enrollment
|
|
Number of participants who require transfer to tertiary care centers
Aikaikkuna: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
Participants who require transfer to tertiary care centers as documented in the medical records. |
From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
|
|
Number of participants who received antenatal corticosteroid administration
Aikaikkuna: Between 24 weeks and 34 weeks of gestation
|
Participants who receive antenatal corticosteroid administration as documented in the medical records. |
Between 24 weeks and 34 weeks of gestation
|
|
Number of preterm births less than 37 weeks
Aikaikkuna: From enrollment up to 36 weeks and 6 days of pregnancy
|
Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods. |
From enrollment up to 36 weeks and 6 days of pregnancy
|
|
Number of early preterm births
Aikaikkuna: From enrollment up to 31 weeks and 6 days of pregnancy
|
Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation. |
From enrollment up to 31 weeks and 6 days of pregnancy
|
|
Composite Adverse Fetal/Neonatal Outcomes
Aikaikkuna: From maternal enrollment through 28 days after birth
|
Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups. |
From maternal enrollment through 28 days after birth
|
|
Length of hospital admission (mother's) of stay,
Aikaikkuna: From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
Length of hospital admission, extracted from medical records |
From admission until post-natal hospital discharge (on average 10 days post-delivery)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Päätutkija: Suchitra Chandrasekaran, MD, Emory University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 2026P000788
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.
The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.
IPD-jaon aikakehys
No specific end date has been established.
IPD-jaon käyttöoikeuskriteerit
Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .